I had listened to the presentation (X3) and share your observation that NASH will be self-funded. Based on potential funding, he plans to go first with NASH, then follow-on with Oncology and HIV/NASH. He is looking for a partner or funding for the last two indications.

I suspect NASH has a shorter timeline to approval than cancer or HIV. Although he did not state this. It's indicated in his time-line chart. Also, less competition and a big market as was stated in the CC...

Can't rule out a potential partner after the trial gets rolling and our hold is lifted.

And then there's Amarex...